December 27, 2012
The Stock Freak has a team of well diverse market professionals that has combined experience of over 30 years that today are providing members with a quick research report on 4 companies.
Amarantus Biosciences (OTC:AMBS) - Amarantus Biosciences, Inc., a development-stage biotechnology company, focuses on the discovery and development of therapeutic proteins and biologics for the treatment of Parkinson's disease, traumatic brain injury (TBI), and other human diseases in
the United States
. AMBS was up 70% during the trading day yesterday with the company announcing that it has acquired Neurodegenerative Diagnostic Intellectual Property Portfolio from Power3 Medical Products.
Whether bull or bear The Stock Freak has got you covered! Sign up to receive our free newsletters and stay up to date with stocks on the run.
Cellceutix Corporation (OTC:CTIX) Cellceutix Corporation has once again made to one of the most active traded stocks on the OTC markets. Yesterday the stock opened at
traded more than 2 million shares with above average volume to close at
representing a gain of 9%.
World Moto (OTC:FARE) World Moto Still continues to be one of the most active stocks in the OTC markets. The company released news yesterday stating that it has introduced a comprehensive road map to advance the global motorcycle taxi industry.
, CTO for World Moto, stated, "The potential that the current motorcycle taxi fleets represent is enormous, and the similarities of the industry to the early days of the internet cannot be ignored."
Facebook Inc (NASDAQ:FB) - Facebook said on Thursday of last week that it has begun testing a system that would allow people to send messages to people outside of their immediate social contact for a payment of
2012 Chief operating Officer
sold 226,341 shares at
price per share for a total sum of
Ford Motor Company (NYSE:F) - Ford Motor Company was one of the most active stocks traded yesterday on the NYSE. The Stock traded over 140 million shares closing up 3%. On
sold 40,000.00 shares
To find similar research reports that are available for free follow the link below and sign up at
Disclosure: TheStockFreak.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. The Stock Freak is a wholly owned entity of a financial public relations firm. Please read our report and visit our website, for complete risks and disclosures.